PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent

 
• By Emily Hayes

ODYSSEY outcomes study homes in on value of PCSK9 inhibition for the subgroup of patients with LDL of at least 100 mg/dL, a potentially large market, but how much will payers ease restrictions in exchange for a lower price?

Arteries swelling because blood clot by fat cloged made blood flow slowly. Illustration about danger of Cholesterol.

More from Drug Pricing

More from Scrip